

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

BRISTOL-MYERS SQUIBB COMPANY and)	
PFIZER INC.,)	
)	
Plaintiffs and Counterclaim-Defendants)	
)	
v.)	C.A. No. 17-374-LPS
)	(CONSOLIDATED)
AUROBINDO PHARMA USA INC. and)	
AUROBINDO PHARMA LTD.,)	
)	
Defendants and Counterclaim-Plaintiffs.)	


BRISTOL-MYERS SQUIBB COMPANY)	
and PFIZER INC.,)	
)	
Plaintiffs,)	
)	
v.)	C.A. No. 17-379-LPS
)	
MYLAN PHARMACEUTICALS INC.,)	
)	
Defendant.)	

ORDER

At Wilmington, this **18th** day of **October, 2018**:

For the reasons set forth in the Memorandum Opinion issued on this date,

IT IS HEREBY ORDERED that Defendant Mylan Pharmaceuticals Inc.’s Motion to Dismiss or Transfer Under 28 U.S.C. § 1406(a) for Improper Venue (C.A. No. 17-379 D.I. 178) is **GRANTED**. **IT IS FURTHER ORDERED** that the parties shall meet and confer and, no later than **October 22, 2018**, submit a joint status report and any necessary or requested order to implement today’s decision.



 UNITED STATES DISTRICT JUDGE